Royalty Pharma PLC (RPRX) Earnings Report: A Detailed Analysis [Yahoo! Finance]
Royalty Pharma plc - Class A Ordinary Shares (RPRX)
US:NASDAQ Investor Relations:
ir.reprosrx.com/investor-relations
Company Research
Source: Yahoo! Finance
Operating Activities : Net cash provided by operating activities reached $773 million in Q4 and $2,988 million for FY 2023. Transactions : Announced transactions valued at up to $4.0 billion in 2023. 2024 Guidance : Portfolio Receipts expected to be between $2,600 million and $2,700 million, reflecting a 5% to 9% growth. Share Repurchase : Approximately 957,000 shares repurchased for $26 million in Q4, totaling 10 million shares for $305 million in 2023. Debt Profile : Total debt stood at $6.3 billion as of December 31, 2023. Warning! GuruFocus has detected 4 Warning Signs with RPRX. Royalty Pharma PLC ( NASDAQ:RPRX ) released its 8-K filing on February 15, 2024, detailing its financial results for the fourth quarter and the full year of 2023. The company, known as the largest buyer of biopharmaceutical royalties, reported a mixed performance with a notable increase in full-year Portfolio Receipts despite a quarterly decline. Company Overview Royalty Pharma PLC operat
Show less
Read more
Impact Snapshot
Event Time:
RPRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RPRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RPRX alerts
High impacting Royalty Pharma plc - Class A Ordinary Shares news events
Weekly update
A roundup of the hottest topics
RPRX
News
- Arrowhead Pharmaceuticals Earns $50 Million Milestone from Royalty Pharma [Yahoo! Finance]Yahoo! Finance
- Royalty Pharma (NASDAQ:RPRX) Will Pay A Dividend Of $0.21 [Yahoo! Finance]Yahoo! Finance
- Royalty Pharma to Announce First Quarter 2024 Financial Results on May 9, 2024GlobeNewswire
- Royalty Pharma Declares Second Quarter 2024 DividendGlobeNewswire
- Royalty Pharma plc (NASDAQ: RPRX) had its price target lowered by analysts at Bank of America Co. from $40.00 to $38.00. They now have a "buy" rating on the stock.MarketBeat
RPRX
Sec Filings
- 4/25/24 - Form ARS
- 4/25/24 - Form DEFA14A
- 4/25/24 - Form DEF
- RPRX's page on the SEC website